CKD Definition & Staging - Know The Score
- Definition: Kidney damage (e.g., albuminuria) OR Glomerular Filtration Rate (GFR) <60 mL/min/1.73m² for >3 months.
- Staging (KDIGO 2012): Classified by cause, GFR category (G-stage), and albuminuria category (A-stage).
| GFR Stage | GFR (mL/min/1.73m²) | Description |
|---|---|---|
| G1 | ≥90 | Normal or high |
| G2 | 60-89 | Mildly decreased |
| G3a | 45-59 | Mildly-moderately ↓ |
| G3b | 30-44 | Moderately-severely ↓ |
| G4 | 15-29 | Severely decreased |
| G5 | <15 | Kidney Failure |
| Albuminuria Stage | ACR (mg/g) | Description |
|---|---|---|
| A1 | <30 | Normal to mildly ↑ |
| A2 | 30-300 | Moderately ↑ |
| A3 | >300 | Severely ↑ |
CKD Etiology - The Usual Suspects
-
Diabetes Mellitus (#1 Cause):
- Hyperglycemia → non-enzymatic glycation of proteins → GBM thickening.
- Leads to diabetic nephropathy.
- Pathognomonic finding: Kimmelstiel-Wilson lesions (nodular glomerulosclerosis).
-
Hypertension (#2 Cause):
- Chronic high pressure damages renal vessels → nephrosclerosis.
- Causes hyaline arteriolosclerosis of small arterioles.
- Leads to glomerulosclerosis and interstitial fibrosis.

⭐ In diabetic nephropathy, the earliest detectable change is microalbuminuria. Regular screening is crucial for early intervention.
CKD Pathophysiology - The Vicious Cycle
-
Hyperfiltration Hypothesis: The final common pathway in CKD. Initial nephron loss from any cause (e.g., diabetes, HTN) forces remaining nephrons to increase their single-nephron GFR to compensate.
-
The Cycle:
- This sustained hyperfiltration ↑ glomerular capillary pressure and shear stress.
- Causes endothelial and podocyte injury, leading to glomerulosclerosis.
- Results in proteinuria and progressive interstitial fibrosis.
- Ultimately, this destroys more nephrons, perpetuating the cycle.

- Key Mediators:
- Angiotensin II: Drives efferent arteriole vasoconstriction (↑ pressure) and stimulates TGF-β.
- TGF-β: Key cytokine promoting fibrosis.
- Proteinuria: Directly toxic to tubular cells, causing inflammation and scarring.
⭐ ACE inhibitors and ARBs slow CKD progression by blocking Angiotensin II, thus dilating the efferent arteriole, which decreases intraglomerular pressure and reduces proteinuria.
Systemic Complications - Uremia's Domino Effect
| Complication | Pathophysiology & Key Features |
|---|---|
| Anemia | Normocytic anemia from ↓ erythropoietin (EPO) production. Iron deficiency may coexist. |
| CKD-Mineral Bone Disorder (MBD) | ↓ active Vit D & ↑PO₄ retention → ↓serum $Ca^{2+}$ → ↑PTH (secondary hyperparathyroidism) & ↑FGF-23. Leads to renal osteodystrophy. |
| Metabolic Acidosis | Impaired excretion of H⁺ and reabsorption of $HCO_3^−$, leading to a high anion gap metabolic acidosis. |
| Uremic Syndrome | Accumulation of waste products. Manifests as encephalopathy (asterixis), uremic pericarditis, and platelet dysfunction (bleeding). |
High‑Yield Points - ⚡ Biggest Takeaways
- Diabetes and hypertension are the leading causes of CKD.
- Pathophysiology involves nephron loss, leading to compensatory hyperfiltration and eventual glomerulosclerosis.
- Persistent albuminuria is a key marker of kidney damage and predicts progression.
- Uremic symptoms manifest late, typically when GFR is <15 mL/min.
- Major complications include anemia (↓ EPO), mineral and bone disorder (secondary hyperparathyroidism), and metabolic acidosis.
- ACE inhibitors/ARBs are crucial for slowing progression, especially with proteinuria.
Continue reading on Oncourse
Sign up for free to access the full lesson, plus unlimited questions, flashcards, AI-powered notes, and more.
CONTINUE READING — FREEor get the app